CN114381513B - 一种与x连锁淋巴增生症相关的生物标志物及其应用 - Google Patents
一种与x连锁淋巴增生症相关的生物标志物及其应用 Download PDFInfo
- Publication number
- CN114381513B CN114381513B CN202210034910.6A CN202210034910A CN114381513B CN 114381513 B CN114381513 B CN 114381513B CN 202210034910 A CN202210034910 A CN 202210034910A CN 114381513 B CN114381513 B CN 114381513B
- Authority
- CN
- China
- Prior art keywords
- linked lymphoproliferative
- lymphoproliferative disorder
- sh2d1a
- gene
- mutation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000030289 Lymphoproliferative disease Diseases 0.000 title claims abstract description 42
- 239000000090 biomarker Substances 0.000 title claims abstract description 21
- 101150010819 SH2D1A gene Proteins 0.000 claims abstract description 31
- 206010068348 X-linked lymphoproliferative syndrome Diseases 0.000 claims abstract description 21
- 208000029625 X-linked lymphoproliferative disease due to SH2D1A deficiency Diseases 0.000 claims description 11
- 201000001271 X-linked lymphoproliferative syndrome 1 Diseases 0.000 claims description 10
- 101150101997 XLP1 gene Proteins 0.000 claims description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 238000009007 Diagnostic Kit Methods 0.000 claims description 4
- 150000007523 nucleic acids Chemical group 0.000 claims description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 239000011535 reaction buffer Substances 0.000 claims description 2
- 230000035772 mutation Effects 0.000 abstract description 33
- 102100027720 SH2 domain-containing protein 1A Human genes 0.000 abstract description 17
- 208000033779 X-linked lymphoproliferative disease Diseases 0.000 abstract description 15
- 108090000623 proteins and genes Proteins 0.000 abstract description 12
- 108010011033 Signaling Lymphocytic Activation Molecule Associated Protein Proteins 0.000 abstract description 10
- 208000015177 X-linked erythropoietic protoporphyria Diseases 0.000 abstract description 10
- 238000013399 early diagnosis Methods 0.000 abstract description 9
- 230000009286 beneficial effect Effects 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 238000012216 screening Methods 0.000 abstract description 5
- 238000001228 spectrum Methods 0.000 abstract description 5
- 238000004458 analytical method Methods 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- 238000000034 method Methods 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 238000012163 sequencing technique Methods 0.000 description 8
- 101000650863 Homo sapiens SH2 domain-containing protein 1A Proteins 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000003550 marker Substances 0.000 description 6
- 206010064571 Gene mutation Diseases 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 241000700605 Viruses Species 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 238000012257 pre-denaturation Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000010008 shearing Methods 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000483399 Ipimorpha retusa Species 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000012453 X-linked lymphoproliferative disease due to XIAP deficiency Diseases 0.000 description 1
- 201000001270 X-linked lymphoproliferative syndrome 2 Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 210000004090 human X chromosome Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000005830 kidney abnormality Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000031942 natural killer cell mediated cytotoxicity Effects 0.000 description 1
- 230000037434 nonsense mutation Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
本发明公开了一种与X连锁淋巴增生症相关的生物标志物及其应用。所述生物标志物包括SH2D1A基因,所述SH2D1A基因NM_002351第2号外显子c.154_201+87inv倒位突变。本发明首次发现SH2D1A基因NM_002351:exon2:c.154_201+87inv倒位突变与XLP疾病密切相关,能够导致X连锁淋巴增生症的发生,在一定程度上扩充了SH2D1A基因的突变谱,有利于X连锁淋巴增生症的早期诊断和筛查。
Description
技术领域
本发明属于生物医学技术领域,涉及一种与X连锁淋巴增生症相关的生物标志物及其应用。
背景技术
X连锁淋巴增生症(X-linked lymphoproliferative disease,XLP),又称X连锁淋巴组织增生综合征,包括XLP1和XLP2两个亚型,XLP1型是最常见的类型(约占60%),它是由编码信号淋巴细胞激活分子(SLAM)相关蛋白(SAP,也称为SH2结构域蛋白1A[SH2D1A]或DSHP)基因突变引起的一种X连锁隐性遗传病,SAP缺陷会导致淋巴细胞对EB病毒应答中发生无限制增殖,并且出现自然杀伤(NK)细胞功能障碍,以EBV感染后的暴发性传染性单核细胞增多症、异常免疫球蛋白血症及B细胞淋巴瘤为主要临床特点。
SH2D1A基因半合子(男性)或纯合突变(女性),导致SAP蛋白表达减少,不能正常参与免疫细胞间的信号转导,而致T/B细胞相互作用异常、使NK细胞介导的细胞毒作用缺陷,最终导致XLP1的发生。
SH2D1A基因位于于人X染色体q25上,全长2523bp,编码129个氨基酸,蛋白细胞浆表达,NCBI Gene ID:4068,SH2D1A基因突变类型包括插入、缺失、错义及剪切突变等。值得注意的是,突变类型与临床表型的严重程度不相关,所以与XLP1的鉴别诊断主要依赖于基因检测,尽早的诊断及进行造血干细胞移植,对XLP患者预后改善十分重要。
现有技术中常通过检测SH2D1A基因突变来辅助诊断XLP-1型X连锁淋巴增生症,基因突变形式包括大片段缺失、小片段缺失、无义突变、错义突变和剪切异常,如郭霞等公开了127种与XLP-1型X连锁淋巴增生症相关的SH2D1A基因突变(参见:郭霞,唐雪,高举,等.X-连锁淋巴增殖性疾病分子机制和诊治进展[J].国际输血及血液学杂志,2018,41(5):5.),然而并不能完全表征所有XLP-1型X连锁淋巴增生症患者。
综上所述,补充开发新的XLP-1型X连锁淋巴增生症的检测标志物指标,以提高检出率,对于X连锁淋巴增生症治疗领域具有重要意义。
发明内容
针对现有技术的不足和实际需求,本发明提供一种与X连锁淋巴增生症相关的生物标志物及其应用,本发明首次发现SH2D1A基因NM_002351第2号外显子c.154_201+87inv倒位突变与X连锁淋巴增生症密切相关,从而可将其作为检测X连锁淋巴增生症的标志物,扩充了SH2D1A基因的突变谱,有利于X连锁淋巴增生症的早期诊断和筛查。
为达上述目的,本发明采用以下技术方案:
第一方面,本发明提供一种与X连锁淋巴增生症相关的生物标志物,所述生物标志物包括SH2D1A基因,所述SH2D1A基因NM_002351第2号外显子c.154_201+87inv倒位突变。
本发明首次发现SH2D1A基因一个新的突变位点,与SH2D1A野生型基因相比,核苷酸NM_002351:exon2:c.154_201+87inv倒位突变,且与XLP疾病密切相关,c.154_201+87inv倒位突变可造成mRNA发生异常剪切,并或可诱发无义介导的mRNA提前降解,形成截短蛋白,造成SAP蛋白发生缺陷,导致淋巴细胞对EB病毒应答中发生无限制增殖以及自然杀伤(NK)细胞功能障碍,进而导致X连锁淋巴增生症的发生。在一定程度上扩充了SH2D1A基因的突变谱,有利于X连锁淋巴增生症的早期诊断和筛查。
优选地,所述SH2D1A基因的核酸序列包括SEQ ID NO.1所示的序列。
SEQ ID NO.1:
CATACCGAGTGTCCCAGACAGAAACAGGTTCTTGGAGTGCTGAGGTATAGTTGTATTTATTTTTGCTTCTGGGGGTGTCAAGGAGGTATTTGAAATTTAGGCTGGTTTTATAAAAGAGCAAATTATACATT。
第二方面,本发明提供检测第一方面所述的与X连锁淋巴增生症相关的生物标志物的引物,所述引物的核酸序列包括SEQ ID NO.2、SEQ ID NO.3和SEQ ID NO.4所示的序列。
SEQ ID NO.2:GGAAACTGTGGTTGGGCAGA。
SEQ ID NO.3:TGCAAAATGATGGCTAAACAGGA。
SEQ ID NO.4:ACCTCCTTGACACCCCCAGA。
本发明采用独特策略设计检测所述的与X连锁淋巴增生症相关的生物标志物的引物,所述引物特异性强,扩增效果好。
第三方面,本发明提供第一方面所述的与X连锁淋巴增生症相关的生物标志物在制备诊断X连锁淋巴增生症的产品中的应用。
第四方面,本发明提供一种X连锁淋巴增生症诊断试剂盒,所述诊断试剂盒包括第二方面所述的检测第一方面所述的与X连锁淋巴增生症相关的生物标志物的引物。
优选地,所述试剂盒还包括dNTPs、DNA聚合酶、Mg2+和PCR反应缓冲液。
优选地,所述试剂盒还包括标准品和/或对照品。
本发明基于所述与X连锁淋巴增生症相关的生物标志物,设计直接检测SH2D1A基因NM_002351第2号外显子c.154_201+87inv倒位突变的试剂盒,可快速检测样本中是否存在突变基因,以辅助X连锁淋巴增生症早期诊断。
第五方面,本发明提供一种第四方面所述的与X连锁淋巴增生症诊断试剂盒以非疾病诊断为目的的使用方法,所述使用方法包括:
以样本基因组为模板,使用所述与X连锁淋巴增生症相关的生物标志物的引物进行PCR扩增,对所述PCR扩增产物进行分析及结果判读。
本发明中,利用X连锁淋巴增生症诊断试剂盒通过特异性引物,扩增获得SH2D1A基因所有外显子区域及包含SH2D1A基因NM_002351第2号外显子c.154_201+87inv的区域,对扩增产物测序,随后进行SH2D1A基因NM_002351第2号外显子c.154_201+87inv的扩增产物片段分析以及SH2D1A基因NM_002351第2号外显子c.154_201+87inv的基因型及其他致病变异分析,可充分获取SH2D1A基因NM_002351第2号外显子c.154_201+87inv突变信息,从而辅助X连锁淋巴增生症早期诊断。
优选地,所述PCR扩增的程序包括:
94~96℃预变性1~4min;
94~96℃变性8~12s,58~62℃退火25~33s,70~74℃延伸55~60s,进行30个循环;
70~74℃延伸1~3min。
优选地,所述分析包括对SH2D1A基因NM_002351第2号外显子c.154_201+87inv区的基因型进行分析。
优选地,所述SH2D1A基因NM_002351第2号外显子c.154_201+87inv区的基因型可通过本领域常规技术方法包括但不限于倒位PCR、Southern印迹法、DNA序列分析、原位杂交等进行检测。
优选地,所述结果判读包括所述SH2D1A基因NM_002351第2号外显子c.154_201+87inv区的基因型为倒位突变,则判断检测对象为候选X连锁淋巴增生症患者。
与现有技术相比,本发明具有以下有益效果:
(1)本发明首次发现SH2D1A基因一个新的突变位点,与SH2D1A野生型基因相比,核苷酸NM_002351:exon2:c.154_201+87inv倒位突变,且与XLP疾病密切相关,可作为X连锁淋巴增生症早期诊断的生物标志物,在一定程度上扩充了SH2D1A基因的突变谱,有利于X连锁淋巴增生症的早期诊断和筛查;
(2)本发明基于所述X连锁淋巴增生症相关的生物标志物,采用独特侧策略设计检测所述标志物的引物,并构建检测SH2D1A基因NM_002351第2号外显子c.154_201+87inv倒位突变的试剂盒,所述试剂盒操作简单、成本低且检测周期短,具有广阔的应用前景。
附图说明
图1为先证者家系图,Ⅰ-1为先证者外婆的姐妹1,Ⅰ-2为先证者外婆的姐妹2,Ⅰ-3为先证者外婆,Ⅱ-1为先证者外婆的姐妹1的女儿,Ⅱ-2为先证者的父亲,Ⅱ-3为先证者的母亲,Ⅱ-4为先证者的舅舅,Ⅲ-1为先证者;
图2为SH2D1A基因2号外显子扩增产物琼脂糖凝胶电泳图,其中M为DNA Marker,Ⅰ-1为先证者外婆的姐妹1,Ⅰ-2为先证者外婆的姐妹2,Ⅰ-3为先证者外婆,Ⅱ-1为先证者外婆的姐妹1的女儿,Ⅱ-2为先证者的父亲,Ⅱ-3为先证者的母亲,Ⅱ-4为先证者的舅舅,Ⅲ-1为先证者;
图3为SH2D1A基因cDNA跨2号外显子序列扩增示意图;
图4为测序结果比对图。
具体实施方式
为进一步阐述本发明所采取的技术手段及其效果,以下结合实施例和附图对本发明作进一步地说明。可以理解的是,此处所描述的具体实施方式仅仅用于解释本发明,而非对本发明的限定。
实施例中未注明具体技术或条件者,按照本领域内的文献所描述的技术或条件,或者按照产品说明书进行。所用试剂或仪器未注明生产厂商者,均为可通过正规渠道商购获得的常规产品。
实施例1
本实施例获取生物样品并进行DNA提取。
2020年,门诊收取一患者,临床表型为:无明显诱因出现下肢疼痛,胸腹盆CT:肝脾大,肺部感染,双肾异常信号,纤支镜:支气管内膜炎症;EB病毒感染;家族无遗传病史。
取患者(作为先证者)及其家系(家系图如图1所示)血液样本并利用磁珠法提取血液样本中基因组DNA,利用分光光度计测量DNA的浓度及纯度,所得的每个样本基因组DNA的OD260/OD280均位于1.7~2.0之间,浓度不少于30ng/μL,总量不少于2μg。
实施例2
本实施例对实施例1获取的样本DNA进行检测,包括以下步骤:
(1)参考人类基因组序列数据库,设计SH2D1A基因1-4号外显子序列分别对应的PCR特异性引物对,如表1所示;
表1
(2)PCR反应体系如表2所示,PCR扩增程序为:95℃预变性2min;95℃变性10s,60℃退火30s,72℃延伸60s,进行30个循环;最后72℃延伸2min,于4℃保存;
表2
(3)PCR扩增结束后,取5μL扩增产物,进行1%琼脂糖凝胶电泳,电泳30min,染色20min,然后将凝胶块置于凝胶成像仪中观察,根据比对Marker的片段大小情况,初步判断扩增片段是否正确,进而对符合要求的扩增产物进行纯化,采用PCR产物纯化试剂盒,并按试剂盒要求进行操作,上样测序:采用ABI公司BigDye3.1SequencingKit试剂盒,并按试剂盒要求进行操作;用ABI公司3730型测序仪进行测序;
(4)2号外显子扩增产物采用Bioptic公司Standard Cartridge Kit(S2)试剂盒,并按试剂盒要求进行操作;用Bioptic公司Qseq100片段分析仪进行分析;
(5)测序结果通过Chromas序列分析软件,将测序结果与标准序列进行比对,寻找突变位点;片段分析结果通过预期扩增片段长度分析,当只有454bp和297bp产物时,结果为野生型,当只有201bp产物时,结果为纯合突变,当结果同时存在454bp、297bp和201bp产物时,结果为杂合突变;
结果如图2所示,分析结果如下:患者片段分析结果只有201bp产物,为纯合突变(男性:半合子突变),患者父亲片段分析结果只有454bp和297bp产物,为野生型;患者母亲片段分析结果同时存在454bp、297bp和201bp产物,为杂合突变,测序结果未发现其他基因突变。
实施例3
本实施例进一步验证SH2D1A基因NM_002351第2号外显子c.154_201+87inv倒位突变与X连锁淋巴增生症关系,包括以下步骤:
(1)利用Trizol法提取患者及其父母血液样本中RNA,利用分光光度计测量RNA的浓度及纯度,所得的每个样本RNA的OD260/OD280均位于1.8~2.0之间,浓度不少于100ng/μL,总量不少于5μg,对提取的RNA进行逆转录得到cDNA产物;
(2)参考人类基因组序列数据库,设计SH2D1A基因cDNA跨2号外显子序列对应的PCR特异性引物对(扩增示意图如图3所示),引物序列如表3所示;
表3
(3)PCR反应体系如表4所示,PCR扩增程序为:95℃预变性2min;95℃变性10s,60℃退火30s,72℃延伸60s,进行30个循环;最后72℃延伸2min,于4℃保存;
表4
组分 | 加入量(μL) |
2×PCR mix | 25 |
引物mix(5μM) | 3 |
cDNA模板 | 2 |
灭菌双蒸水 | 20 |
(4)PCR扩增结束后,取5μL扩增产物,进行1%琼脂糖凝胶电泳,电泳30min,染色20min,然后将凝胶块置于凝胶成像仪中观察,根据比对Marker的片段大小情况,初步判断扩增片段是否正确,进而对符合要求的扩增产物进行纯化:采用PCR产物纯化试剂盒,并按试剂盒要求进行操作,上样测序:采用ABI公司BigDye3.1SequencingKit试剂盒,并按试剂盒要求进行操作;用ABI公司3730型测序仪进行测序;
(5)结果分析:测序结果通过Chromas序列分析软件,将测序结果与标准序列进行比对,结果如图4所示,分析结果确认患者mRNA中因异常剪切造成外显子2纯合缺失,患者父亲为野生型,患者母亲为杂合突变。
综上所述,本发明首次发现SH2D1A基因一个新的突变位点,与SH2D1A野生型基因相比,核苷酸NM_002351:exon2:c.154_201+87inv倒位突变,且与XLP疾病密切相关,c.154_201+87inv倒位突变可造成mRNA发生异常剪切,并或可诱发无义介导的mRNA提前降解,形成截短蛋白,造成SAP蛋白发生缺陷,导致淋巴细胞对EB病毒应答中发生无限制增殖以及自然杀伤(NK)细胞功能障碍,进而导致X连锁淋巴增生症的发生。在一定程度上扩充了SH2D1A基因的突变谱,有利于X连锁淋巴增生症的早期诊断和筛查。
申请人声明,本发明通过上述实施例来说明本发明的详细方法,但本发明并不局限于上述详细方法,即不意味着本发明必须依赖上述详细方法才能实施。所属技术领域的技术人员应该明了,对本发明的任何改进,对本发明产品各原料的等效替换及辅助成分的添加、具体方式的选择等,均落在本发明的保护范围和公开范围之内。
序列表
<110> 苏州赛福医学检验有限公司
<120> 一种与X连锁淋巴增生症相关的生物标志物及其应用
<130> 2022-01-11
<160> 4
<170> PatentIn version 3.3
<210> 1
<211> 131
<212> DNA
<213> 人工序列
<400> 1
cataccgagt gtcccagaca gaaacaggtt cttggagtgc tgaggtatag ttgtatttat 60
ttttgcttct gggggtgtca aggaggtatt tgaaatttag gctggtttta taaaagagca 120
aattatacat t 131
<210> 2
<211> 20
<212> DNA
<213> 人工序列
<400> 2
ggaaactgtg gttgggcaga 20
<210> 3
<211> 23
<212> DNA
<213> 人工序列
<400> 3
tgcaaaatga tggctaaaca gga 23
<210> 4
<211> 20
<212> DNA
<213> 人工序列
<400> 4
acctccttga cacccccaga 20
Claims (4)
1.检测与X连锁淋巴增生症XLP1亚型相关的生物标志物试剂在制备诊断X连锁淋巴增生症XLP1亚型的产品中的应用;
所述生物标志物为SH2D1A基因NM_002351第2号外显子c.154_201+87inv;
所述SH2D1A基因的核酸序列如SEQ ID NO.1所示。
2.一种X连锁淋巴增生症XLP1亚型诊断试剂盒,其特征在于,所述诊断试剂盒包括检测权利要求1所述的与X连锁淋巴增生症XLP1亚型相关的生物标志物的引物。
3.根据权利要求2所述的X连锁淋巴增生症XLP1亚型诊断试剂盒,其特征在于,所述引物的核酸序列包括SEQ ID NO.2、SEQ ID NO.3和SEQ ID NO.4所示的序列。
4.根据权利要求2所述的X连锁淋巴增生症XLP1亚型诊断试剂盒,其特征在于,所述试剂盒还包括dNTPs、DNA聚合酶、Mg2+和PCR反应缓冲液。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210034910.6A CN114381513B (zh) | 2022-01-13 | 2022-01-13 | 一种与x连锁淋巴增生症相关的生物标志物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210034910.6A CN114381513B (zh) | 2022-01-13 | 2022-01-13 | 一种与x连锁淋巴增生症相关的生物标志物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114381513A CN114381513A (zh) | 2022-04-22 |
CN114381513B true CN114381513B (zh) | 2024-02-13 |
Family
ID=81201627
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210034910.6A Active CN114381513B (zh) | 2022-01-13 | 2022-01-13 | 一种与x连锁淋巴增生症相关的生物标志物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114381513B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103740827A (zh) * | 2014-01-13 | 2014-04-23 | 香港中文大学深圳研究院 | 胎儿dna芯片及其应用 |
-
2022
- 2022-01-13 CN CN202210034910.6A patent/CN114381513B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103740827A (zh) * | 2014-01-13 | 2014-04-23 | 香港中文大学深圳研究院 | 胎儿dna芯片及其应用 |
Non-Patent Citations (3)
Title |
---|
Exon skipping caused by a complex structural variation in SH2D1A resulted in X-linked lymphoproliferative syndrome type 1;Liwen Wu et al;Mol Genet Genomic Me;第10卷;第1-8页 * |
X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease;Claire Booth et al;Blood;第111卷(第1期);第53-62页 * |
X连锁淋巴组织细胞异常增生症研究进展;陈兰勤;刘春燕;申昆玲;;中国实用儿科杂志(04);第309-311页 * |
Also Published As
Publication number | Publication date |
---|---|
CN114381513A (zh) | 2022-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109735610B (zh) | 一种用于检测类孟买血型的基因多态性位点 | |
CN114703278A (zh) | 一种肌萎缩侧索硬化致病基因、检测试剂盒及引物组 | |
CN113637776A (zh) | 专用于Diego血型基因测序的引物组及试剂盒和方法 | |
CN114381513B (zh) | 一种与x连锁淋巴增生症相关的生物标志物及其应用 | |
CN112280852B (zh) | 一种smn1基因突变检测试剂盒及其应用 | |
CN116926185A (zh) | 常染色体显性多囊肾病致病基因突变检测 | |
CN103045722B (zh) | 结晶样先天性白内障致病基因crygd检测试剂盒 | |
CN112226440B (zh) | 一种遗传性原发不孕的致病突变及其检测试剂 | |
CN114292908A (zh) | 检测地中海贫血基因罕见突变的试剂、方法和试剂盒 | |
CN117487907B (zh) | Kcnh2基因突变体、突变体蛋白、试剂、试剂盒及应用 | |
CN113817813B (zh) | 与特殊类型糖尿病相关的基因突变片段及其应用 | |
CN114622013B (zh) | 一种青少年特发性脊柱侧弯检测产品 | |
CN113265409B (zh) | Timm21突变基因、检测其的引物、试剂盒和方法以及其用途 | |
CN117230184B (zh) | 基于飞行时间核酸质谱技术检测阿尔兹海默病基因的核酸组合及应用 | |
CN113444792B (zh) | 一种辅助筛查家族性甲状腺乳头状癌的试剂盒 | |
CN110511992B (zh) | 一种tardbp突变基因、检测引物和试剂盒 | |
CN109735615B (zh) | 一种视网膜色素变性筛查试剂盒 | |
CN110577953B (zh) | 基因突变体及其应用 | |
CN115873861A (zh) | Pah致病突变体及在制备苯丙酮尿症诊断试剂盒中的应用 | |
CN115948534A (zh) | Ripk1基因突变形式在诊断自身炎症伴阵发发热和淋巴结肿大中的应用 | |
KR101107570B1 (ko) | 제한효소 절편 질량다형성법을 이용한 윌슨병 원인 유전자 변이 검출방법 | |
CN115851749A (zh) | 马凡综合征变异基因fbn1及其应用 | |
CN116496377A (zh) | Ush2a基因突变的多肽、核酸及其应用 | |
CN116606924A (zh) | 一种smn1-smn2融合基因微小突变的检测套组及其应用 | |
CN116479111A (zh) | 一种先天性无瞳孔-小眼球-白内障综合征筛查方法、筛查试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |